Cancer Genetics (CGIX) Sees IPO Price in $11-$13/Share Range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq on track for record closing highs as focus turns to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Citi cuts investment banking analyst program to two years - Bloomberg
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Nasdaq notches record high close as investors focus on earnings
Cancer Genetics (CGIX) Adjusts Expected IPO Price to $10 - $12/Share
March 4, 2013 10:35 AM ESTCancer Genetics (Nasdaq: CGIX) filed an amended registration with the U.S. SEC for an Initial Public Offering of its Common Stock. The company plans to sell 1.85 million shares and sees an offering price of $10 to $12 per share. Prior expectations from the... More



